MaxCyte Inc
LSE:MXCT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
MaxCyte Inc
LSE:MXCT
|
US |
|
N
|
Ningbo Fujia Industrial Co Ltd
SSE:603219
|
CN |
|
Lonseal Corp
TSE:4224
|
JP |
|
L
|
Logan Group Co Ltd
HKEX:3380
|
CN |
|
Fangzhou Inc
HKEX:6086
|
CN |
|
Sonos Inc
NASDAQ:SONO
|
US |
|
S
|
Stor-Age Property REIT Ltd
JSE:SSS
|
ZA |
|
Wus Printed Circuit Co Ltd
TWSE:2316
|
TW |
|
M
|
Maxicity Holdings Ltd
HKEX:2295
|
HK |
MaxCyte Inc
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2016-03-29. The firm is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The firm has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The firm has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2016-03-29. The firm is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The firm has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The firm has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.
Revenue: Total 2025 revenue was $33 million (core $29.6M, SPL $3.4M), down from $38.6M in 2024.
Guidance: 2026 revenue guide $30M–$32M (core $25M–$27M; SPL $5M); company says Q1 will be the lightest quarter for core revenue.
SPL headwinds: Management attributes ~$4M of 2026 core revenue headwind to program rationalizations and inventory/lease changes at its largest SPL customer.
New product: Launched ExPERT DTx (96‑well electroporation) in Feb 2026 and expects initial revenue contribution starting in H2 2026.
Cost and cash: Reduced annual cash burn by >$16M via 2025 restructuring; year-end cash + investments $155.6M and expected at least $136M at end of 2026.
SeQure DX: Acquisition integrated; SeQure revenue was $1.1M in 2025 and is expected to grow year‑over‑year in 2026.
Commercial momentum: One 7‑figure milestone was received in Q1 2026 and management expects ~ $2M of royalty revenue from a commercial partner in 2026 as that therapy ramps.
